With a revenue increase of 1041.37% in the second quarter 2026, year on year to cumulative value of $13 million, Crispr Therapeutics Ag's revenue per employee grew on a trailing twelve months basis to $ 66,627, this is below the company average.
Within the Healthcare sector Employees of 536 other companies have achieved higher revenue per employee. While revenue/employee total ranking has improved so far to 3605, from total ranking in previous quarter at 4175. Crispr Therapeutics Ag has 201 employees.

What is Sales per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Revenue per Employee▼

None ▼

Revenue per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CRSP Revenue per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Revenue Change	1041.37 %	68.55 %	-97.58 %	47.67 %	72.53 %
Sales per Employee (TTM) $	66,627	20,413	17,463	190,731	189,303
CRSP's Total Ranking	# 3605	# 4175	# 3171	# 3176	# 3205
Seq. Revenue Change	598.29 %	68.75 %	-2.81 %	-0.34 %	3.12 %

CRSP Company Profile >> Back to CRSP Efficiency Comparisons >> Compare CRSP Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 66
Healthcare Sector	# 537
Overall Market	# 3605

Revenue per Employee Statistics
High	Average	Low
$ 4,554,050	$ 805,069	$ 3,577
(Mar 31 2022)		(Dec 31 2020)

Financial Statements
Crispr Therapeutics Ag's Revenue MRQ	$ 10 Millions	Visit CRSP's Income Statement
Crispr Therapeutics Ag's Revenues TTM	$ 13 Millions	Visit CRSP's aggregate revenue growth
What are CRSP's Sales?		Visit CRSP's Sales by Segment

News about Crispr Therapeutics Ag Revenue per employee

CRISPR Therapeutics: A Gene Editing Pioneer Struggles Amidst Milestones

Overview of Recent DevelopmentsCRISPR Therapeutics, a trailblazer in the realm of gene editing technologies, has recently made noteworthy progress in the treatment of severe genetic disorders, specifically sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The recent approval of its innovative therapy, CASGEVY (exagamglogene autotemcel), alongside the presentation of promising preliminary data for its drug CTX112 at the 2024 American Society of Hematology (ASH) Annual Meeting, underscores the company’s commitment to transforming patient care through groundbreaking therapies. However, despite these scientific advancements, CRISPR Therapeutics faces a dual challenge: operational efficiency and competitive performance.Key Highlights1. Strategic Milestones: - The launch of CASGEVY has gained momentum, reflecting the company’s strategic prioritization towards innovative therapies in genetic disorders. - The preliminary results of CTX112 indicate potential efficacy and safety, positioning the company as a front-runner in developing solutions for SCD and TDT.

Other Ratios
Crispr Therapeutics Ag's Income per Employee
Employees in Biotechnology & Pharmaceuticals
Biotechnology & Pharmaceuticals Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
CRSP's Revenue per Employee versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for CRSP's Competitors
Revenue per Employee for CRSP's Suppliers
Revenue per Employee for CRSP's Customers

You may also want to know
CRSP's Sales Growth Rates	CRSP's Pe Price to earnings ratio	CRSP's Receivables Turnover Ratio	CRSP's Stock Quote
CRSP's Net Income Growth Rates	CRSP's Ps Price to Sales ratio	CRSP's Sales per Employee	CRSP's Asset Turnover Ratio
CRSP's Net Margin	CRSP's Pb Price to Book ratio	CRSP's Financial Strength Ratios	CRSP's Dividend Payout Ratio

Date modified: 2026-09-12T18:22:26+00:00

Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector	Revenue per Employee	Revenue 12 months ending Jun 30 2026	Number of Employees Jun 30 2026
Renovorx Inc	116,235.29	$ 1.976 Million	17
Nurix Therapeutics Inc	115,981.07	$ 36.766 Million	317
Metagenomi Therapeutics Inc	113,957.98	$ 13.561 Million	119
The Pennant Group Inc	113,578.35	$ 1,101.710 Million	9,700
Amarin Corp Plcuk	113,018.18	$ 186.480 Million	1,650
Catheter Precision Inc	112,647.06	$ 1.915 Million	17
Aclaris Therapeutics Inc	112,589.04	$ 8.219 Million	73
Lipocine Inc	112,104.29	$ 1.569 Million	14
U S Physical Therapy Inc	111,352.21	$ 812.203 Million	7,294
Ss Innovations International Inc	108,071.45	$ 52.199 Million	483
Adm Tronics Unlimited Inc	107,988.73	$ 3.240 Million	30
Teleflex Incorporated	105,066.71	$ 1,628.534 Million	15,500
Bioaffinity Technologies Inc	103,526.05	$ 5.901 Million	57
Caribou Biosciences Inc	103,453.61	$ 10.035 Million	97
Sonida Senior Living Inc	102,329.38	$ 525.973 Million	5,140
National Healthcare Corp	102,043.46	$ 1,559.020 Million	15,278
Seastar Medical Holding Corp	100,764.71	$ 1.713 Million	17
Cytokinetics Incorporated	100,549.78	$ 67.670 Million	673
Armata Pharmaceuticals Inc	98,918.03	$ 6.034 Million	61
Bio Green Med Solution Inc	97,947.37	$ 1.861 Million	19
Brookdale Senior Living Inc	92,445.36	$ 3,050.697 Million	33,000
Recursion Pharmaceuticals Inc	91,425.00	$ 54.855 Million	600
Scienture Holdings Inc	91,257.22	$ 0.821 Million	9
Biomerica Inc	89,060.00	$ 4.453 Million	50
Camp4 Therapeutics Corporation	87,833.33	$ 4.216 Million	48
Sonoma Pharmaceuticals Inc	87,680.00	$ 21.920 Million	250
Inspiremd Inc	82,692.91	$ 10.502 Million	127
Docgo Inc	82,601.04	$ 294.721 Million	3,568
Picard Medical Inc	79,773.33	$ 5.983 Million	75
Vivos Therapeutics Inc	78,861.94	$ 21.135 Million	268

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.